Feb 5, 2026
What are the published toxicity profiles and laboratory monitoring recommendations from the mebendazole phase‑1 cancer trials?
Phase‑1 clinical work repurposing —most notably a dose‑escalation trial in newly diagnosed high‑grade glioma—found “acceptable toxicity,” no severe adverse events attributed to mebendazole at doses up...